A. Rachel Leheny - 24 Jun 2025 Form 4 Insider Report for CalciMedica, Inc. (CALC)

Reporting relationship: CHIEF EXECUTIVE OFFICER, Director, 10%+ Owner
Issuer ticker: CALC
Reported as of: 24 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Jun 2025, 18:26:23 UTC
Prior SEC filing: 25 Apr 2025
Next SEC filing: 15 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ John Dunn, Attorney-in-Fact

Key filing fact

A. Rachel Leheny filed Form 4 for CalciMedica, Inc. (CALC) on 26 Jun 2025.

Key facts

This page summarizes A. Rachel Leheny's Form 4 filing for CalciMedica, Inc. (CALC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 26 Jun 2025, 18:26.

Change

Previous filing in this sequence was filed on 25 Apr 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001484729 Primary reporting owner

Leheny A. Rachel

Relationship: CHIEF EXECUTIVE OFFICER, Director, 10%+ Owner
Address: C/O CALCIMEDICA, INC., 505 COAST BLVD. S. #307, LA JOLLA
Signature: /s/ John Dunn, Attorney-in-Fact
Signature date: 26 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CALC transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +77,625
Change %
Price: $0.000000
Shares after: 77,625
Date: 24 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 77,625
Exercise price: $1.53
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

Footnote F2

Immediately exercisable.